Merck & Company

MRK-N

NYSE:MRK

80.72
1.68 (2.13%)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world.
More at Wikipedia

Analysis and Opinions about MRK-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
May 9, 2002
(Was a top pick on Apr 4 up 1.5%) Still likes.
Show full opinionHide full opinion
(Was a top pick on Apr 4 up 1.5%) Still likes.
DON'T BUY
DON'T BUY
April 22, 2002
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
Show full opinionHide full opinion
Merck & Company (MRK-N)
April 22, 2002
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
DON'T BUY
DON'T BUY
April 19, 2002
Fairly cheap. Dividend. Several drugs coming off patent.
Show full opinionHide full opinion
Merck & Company (MRK-N)
April 19, 2002
Fairly cheap. Dividend. Several drugs coming off patent.
BUY
BUY
April 15, 2002
At a 5 year low. Have some good products. At a good price.
Show full opinionHide full opinion
Merck & Company (MRK-N)
April 15, 2002
At a 5 year low. Have some good products. At a good price.
WEAK BUY
WEAK BUY
April 12, 2002
Expiring patents have created problems. Pipeline is not as strong as other pharmaceuticals, but the price is very cheap.
Show full opinionHide full opinion
Merck & Company (MRK-N)
April 12, 2002
Expiring patents have created problems. Pipeline is not as strong as other pharmaceuticals, but the price is very cheap.
TOP PICK
TOP PICK
April 4, 2002
One of the cheapest in the drug sctor.
Show full opinionHide full opinion
One of the cheapest in the drug sctor.
DON'T BUY
DON'T BUY
March 8, 2002
Losing a lot of their patents with nothing new in the pipeline.
Show full opinionHide full opinion
Losing a lot of their patents with nothing new in the pipeline.
WEAK BUY
WEAK BUY
February 22, 2002
No earnings growth this year. Should be some in 2003. At a good price. Prefers J&J or Pfizer.
Show full opinionHide full opinion
Merck & Company (MRK-N)
February 22, 2002
No earnings growth this year. Should be some in 2003. At a good price. Prefers J&J or Pfizer.
DON'T BUY
DON'T BUY
January 30, 2002
Broke through a technical base. Generics are giving some tough competition.
Show full opinionHide full opinion
Merck & Company (MRK-N)
January 30, 2002
Broke through a technical base. Generics are giving some tough competition.
DON'T BUY
DON'T BUY
January 7, 2002
A lot of their drugs have come off patent without adequate replacement. Prefers Pfizer.
Show full opinionHide full opinion
Merck & Company (MRK-N)
January 7, 2002
A lot of their drugs have come off patent without adequate replacement. Prefers Pfizer.
WAIT
WAIT
December 18, 2001
Competition. Pipeline is weak now. OK long term.
Show full opinionHide full opinion
Merck & Company (MRK-N)
December 18, 2001
Competition. Pipeline is weak now. OK long term.
DON'T BUY
DON'T BUY
December 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Show full opinionHide full opinion
Merck & Company (MRK-N)
December 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
DON'T BUY
DON'T BUY
November 12, 2001
Has been a defensive stock. Overvalued.
Show full opinionHide full opinion
Merck & Company (MRK-N)
November 12, 2001
Has been a defensive stock. Overvalued.
DON'T BUY
DON'T BUY
June 14, 2001
Patent expiries are a concern. Limited pipeline. Arthritis drug not moving well. Prefers Pfizer.
Show full opinionHide full opinion
Patent expiries are a concern. Limited pipeline. Arthritis drug not moving well. Prefers Pfizer.
BUY
BUY
June 6, 2001
Likes both Pfizer and Merck in pharmaceuticals.
Show full opinionHide full opinion
Likes both Pfizer and Merck in pharmaceuticals.
Showing 166 to 180 of 188 entries